+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness of abatacept in patients with Giant Cell Arteritis GCA, a condition involving inflammation of large blood vessels. This phase 3 randomized, double-blind, placebo-controlled trial involves 62 patients newly diagnosed or experiencing a relapse of GCA within 8 weeks before screening. The study aims to compare remission rates between abatacept and placebo over a 12-month period. Participants will be randomly assigned to receive either weekly subcutaneous injections of abatacept 125 mg or placebo for at least 12 months. Those who do not achieve remission by month 3 or who relapse within the first year may enter an open-label phase to receive abatacept treatment for up to 12 additional months. Treatment may stop earlier if disease worsening or relapse occurs. During the study, participants will be monitored for remission status, disease relapse, and safety. Quality of life will be assessed using the SF-36 and PROMIS questionnaires. Researchers will also evaluate the duration of glucocorticoid-free remission from month 6 to month 12. The trial includes regular follow-ups to assess treatment effects and safety over the course of participation, which spans up to 24 months for some participants.

Age: 50Years +All GendersPhase 3
10 locations
L

Actively Recruiting

Eosinophilic granulomatosis with polyangiitis EGPA is a rare immune system disorder characterized by asthma, high levels of eosinophils in the blood, and inflammation of blood vessels affecting various organs. This study aims to identify new biological markers, called biomarkers, that can help assess the severity and activity of EGPA over time. These biomarkers could improve monitoring and guide future treatments for people with EGPA. Participants in this observational study will attend visits every six months or annually, during which blood and urine samples will be collected. At each visit, a physical exam will be performed, medical and medication histories reviewed, and participants will complete questionnaires about their disease activity, health status, and lifestyle factors such as tobacco, alcohol, and drug use. Throughout the study, researchers will measure the biomarkers to evaluate disease activity and how patients respond to treatment. The main goal is to discover biomarkers that can predict clinical outcomes for EGPA. The study will continue until 2028, with ongoing monitoring and assessments at regular intervals to gather comprehensive data on the disease.

All AgesAll Genders
15 locations